Sanofi drops 'intriguing' data on rival to Bristol Myers' bempeg

Sanofi drops 'intriguing' data on rival to Bristol Myers' bempeg

Source: 
Fierce Biotech
snippet: 

Sanofi has posted early-phase data on its recombinant IL-2 molecule in solid tumor patients. Analysts at Jefferies called the data “intriguing” while noting it is currently hard to tell whether the drug improves on the IL-2 pathway agonist Bristol Myers Squibb is developing in partnership with Nektar Therapeutics.